Abu Dhabi: Burjeel Holdings, a leading healthcare provider in the UAE, has recently announced a significant achievement in its pursuit of excellence in personalised cancer medicine. The flagship facility, Burjeel Medical City, has been selected as a member of the Worldwide Innovative Networking in Personalised Cancer Medicine (WIN) Consortium. This accomplishment marks a major milestone for Burjeel Holdings as it expands its network and expertise in oncology, solidifying its position as a trailblazer in personalised cancer care within the UAE and the wider region.
Burjeel Medical City has become the first institution from the UAE and the Gulf Cooperation Council countries to join the esteemed WIN Consortium. As a member, the medical city will serve as an accelerator, fostering regional collaborations in WIN programmes and projects.
The WIN Consortium is a renowned global network comprising more than 30 esteemed organisations from the Americas, EU, and Asia, all specializing in cancer care and research. These institutions represent various stakeholders involved in the patient journey and personalised cancer care. The primary objective of the consortium is to enhance the survival rates and quality of life for cancer patients by leveraging genetically informed healthcare and expediting the discovery and development of highly targeted cancer therapies.
Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings, said, “We are honoured to join the WIN Consortium, which is at the forefront of research in personalised cancer medicine. Through this membership, we are furthering our commitment to providing the best possible care to our patients in the UAE and wider region by collaborating with an elite global team to advance the understanding and treatment of cancer in an era of personalised care. The WIN Consortium provides a unique platform for us to share knowledge, expertise, and data to accelerate the development of innovative solutions and new treatments.”
Membership in the WIN Consortium is a significant milestone for Burjeel Medical City, which aims to establish itself as the regional hub for cancer care, continuously advancing research and innovation initiatives. By joining this exclusive network of experts, the hospital has reaffirmed its commitment to developing targeted cancer therapeutics and aligning strategically with WIN’s mission.
As the newest member of the consortium, Burjeel Medical City holds a unique position to contribute to the future accomplishments of this collective group. With its status as a quaternary care center located in Abu Dhabi, the hospital’s diverse patient pool presents immense potential for valuable contributions to precision medicine studies. In line with its dedication to providing exceptional care and advancing the field of oncology, the hospital has recently invested in offering molecular genetics, cellular, and immunological profile testing in the UAE.
Burjeel Medical City’s representation in the WIN Consortium will be led by esteemed individuals in the field of oncology, Prof. Humaid Al Shamsi, Director of Oncology Services, Burjeel Holdings, and Dr. Khaled Musallam, Group Chief Research Officer, Burjeel Holdings. Their presence in the consortium serves as a testament to the hospital’s unwavering commitment to excellence and its relentless pursuit of advancements in cancer care.
With membership in the WIN Consortium, Burjeel Medical City stands poised to strengthen its leadership position in personalised cancer medicine. Through collaboration with international experts and the collective efforts of the consortium, the hospital aims to revolutionize cancer treatment and significantly improve outcomes for patients in the UAE and beyond.